Acumen Research and Consulting Ophthalmic Drugs Market | Page 2

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/reques t-sample/1323 For example, Nicox was approved for the treatment of ocular itching related to allergic conjunctivitis by FDA for ZERVIATE (cetirizine ophthalmic solution) in 2017. Key companies, including Bausch & Lomb Inc. and Pfizer, Inc., Novartis AG, are involved in fusions & acquisitions in order to increase their market share. This is the very first ocular version of antihistamine. Abbott Medical Optics, Inc. was acquired in 2017 by Johnson & Johnson Services, Inc. With this acquisition, the entire Abbott Medical Optics, Inc. product range will be sold under the name Johnson&Johnson including consumer visual health, laser refractive surgery and cataract surgery. Growth Factors Other key factors that increase the market size of ophthalmic drugs include a world-wide high prevalence of glaucoma and an increase in the transition to combination therapies to treat glaucoma. The population dynamics around the globe also contribute to the growth of the market. However, this growth is impeded by the risk of side effects related to ophthalmic medicines and the longer schedules for new ophthalmic medicine. In addition, increased investment by emerging-economy market players offers lucrative market growth opportunities in the near future. Market Snapshots In 2018, the anti-VEGF agent is leading the market and, due to the widespread use of it for eye conditions such as age related macular degeneration and diabetic retinopathy, is provisionally the fastest CAGR of more than 7.5% between 2019 and 2026. Would like to place an order or any question, please feel free to contact at [email protected] | [phone]